[8-K] Humacyte, Inc. Reports Material Event
Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.
The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre fiscale chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 ed 猫 incorporato per riferimento nel presente Current Report, ma il corpo del Modulo 8-K non include i dati finanziari o le tabelle sottostanti.
La documentazione dichiara esplicitamente che le informazioni, incluso l'allegato, "non devono essere considerate presentate" ai fini della Sezione 18 dell'Exchange Act e non saranno incorporate per riferimento in altri depositi salvo che per specifico riferimento. Il rapporto indica inoltre la societ脿 come emerging growth company e riporta i suoi titoli come Common Stock (HUMA) e Redeemable Warrants (HUMAW) sul Nasdaq. Il deposito include l'Exhibit 99.1 e il Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. public贸 un comunicado de prensa con sus resultados financieros correspondientes al segundo trimestre fiscal concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Current Report, pero el cuerpo del Formulario 8-K no incluye las cifras financieras o las tablas subyacentes.
La presentaci贸n declara expl铆citamente que la informaci贸n, incluido el anexo, "no se considerar谩 presentada" a efectos de la Secci贸n 18 del Exchange Act y no se incorporar谩 por referencia en otros documentos salvo que se haga referencia espec铆fica. El informe tambi茅n identifica a la compa帽铆a como una emerging growth company y enumera sus valores como Common Stock (HUMA) y Redeemable Warrants (HUMAW) en Nasdaq. La presentaci贸n incluye el Exhibit 99.1 y el Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc.電� 須岅硠鞐半弰 鞝�2攵勱赴(膦呺鞚�: 2025雲� 6鞗� 30鞚�)鞚� 鞛 瓴瓣臣毳� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞚� Current Report鞐� 彀胳“搿� 韽暔霅橃毵�, Form 8-K 氤鸽鞐愲姅 旮办磮 鞛 靾橃箻雮� 響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
頃措嫻 鞝滌稖靹滊電� 觳秬氍胳劀毳� 韽暔頃� 鞝曤炒臧� Section 18 of the Exchange Act鞚� 氇╈爜靸� "鞝涤稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婌姷雼堧嫟"霛缄碃 氇呾嫓鞝侅溂搿� 氚濏瀳瓿� 鞛堨溂氅�, 韸轨爼頃� 鞏戈笁鞚� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婌潉 瓴冹澊霛缄碃 氇呾嫓頃╇媹雼�. 氤搓碃靹滊姅 霕愴暅 須岇偓毳� emerging growth company搿� 鞁濍硠頃橁碃 鞛堨溂氅�, 攴� 歃濌秾鞚� Nasdaq鞐愳劀 Common Stock (HUMA) 氚� Redeemable Warrants (HUMAW)搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Exhibit 99.1瓿� Cover Page Interactive Data File (Exhibit 104)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Humacyte, Inc. a diffus茅 un communiqu茅 de presse faisant 茅tat de ses r茅sultats financiers pour le deuxi猫me trimestre fiscal clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et est incorpor茅 par renvoi dans ce Current Report, mais le corps du formulaire 8-K n'inclut pas les chiffres financiers ou les tableaux sous-jacents.
Le document pr茅cise explicitement que les informations, y compris l'annexe, "ne doivent pas 锚tre consid茅r茅es comme 诲茅辫辞蝉茅别蝉" aux fins de la Section 18 de l'Exchange Act et ne seront pas incorpor茅es par renvoi dans d'autres d茅p么ts sauf par r茅f茅rence sp茅cifique. Le rapport identifie 茅galement la soci茅t茅 comme une emerging growth company et indique ses titres comme Common Stock (HUMA) et Redeemable Warrants (HUMAW) sur le Nasdaq. Le d茅p么t comprend l'Exhibit 99.1 et le Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. hat eine Pressemitteilung mit den Finanzergebnissen f眉r das am 30. Juni 2025 endende zweite Gesch盲ftsquartal ver枚ffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und wird in diesen Current Report durch Verweis aufgenommen, doch der Text des Formulars 8-K enth盲lt nicht die zugrundeliegenden Finanzkennzahlen oder Tabellen.
Die Einreichung stellt ausdr眉cklich fest, dass die Informationen, einschlie脽lich des Anhangs, "nicht als eingereicht gelten" im Sinne von Section 18 des Exchange Act und nicht durch Verweis in andere Einreichungen aufgenommen werden, au脽er durch ausdr眉ckliche Nennung. Der Bericht bezeichnet das Unternehmen au脽erdem als emerging growth company und f眉hrt seine Wertpapiere als Common Stock (HUMA) und Redeemable Warrants (HUMAW) an der Nasdaq auf. Der Einreichung sind Exhibit 99.1 und die Cover Page Interactive Data File (Exhibit 104) beigef眉gt.
- None.
- None.
Insights
TL;DR: Routine Form 8-K furnishing a Q2 press release; the filing itself contains no financial statements, so immediate material impact is limited.
The company used Item 2.02 to furnish its fiscal Q2 2025 press release as Exhibit 99.1 and included the Inline XBRL cover page as Exhibit 104. The filing reiterates that the furnished materials are not "filed" under Section 18, which preserves limits on incorporation by reference. For investors, the actionable financial details will appear in the attached press release rather than in this Form 8-K text.
TL;DR: Administrative disclosure consistent with standard SEC practice; the "not filed" language maintains company control over incorporation of the release.
This 8-K follows common governance practice by furnishing a press release and explicitly stating the exhibit will not be treated as "filed" under the Exchange Act. The form lists exhibits clearly (99.1 and 104) and confirms emerging growth company status. There are no governance changes, officer departures, or material agreements disclosed in this report.
Humacyte, Inc. ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre fiscale chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 ed 猫 incorporato per riferimento nel presente Current Report, ma il corpo del Modulo 8-K non include i dati finanziari o le tabelle sottostanti.
La documentazione dichiara esplicitamente che le informazioni, incluso l'allegato, "non devono essere considerate presentate" ai fini della Sezione 18 dell'Exchange Act e non saranno incorporate per riferimento in altri depositi salvo che per specifico riferimento. Il rapporto indica inoltre la societ脿 come emerging growth company e riporta i suoi titoli come Common Stock (HUMA) e Redeemable Warrants (HUMAW) sul Nasdaq. Il deposito include l'Exhibit 99.1 e il Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. public贸 un comunicado de prensa con sus resultados financieros correspondientes al segundo trimestre fiscal concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Current Report, pero el cuerpo del Formulario 8-K no incluye las cifras financieras o las tablas subyacentes.
La presentaci贸n declara expl铆citamente que la informaci贸n, incluido el anexo, "no se considerar谩 presentada" a efectos de la Secci贸n 18 del Exchange Act y no se incorporar谩 por referencia en otros documentos salvo que se haga referencia espec铆fica. El informe tambi茅n identifica a la compa帽铆a como una emerging growth company y enumera sus valores como Common Stock (HUMA) y Redeemable Warrants (HUMAW) en Nasdaq. La presentaci贸n incluye el Exhibit 99.1 y el Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc.電� 須岅硠鞐半弰 鞝�2攵勱赴(膦呺鞚�: 2025雲� 6鞗� 30鞚�)鞚� 鞛 瓴瓣臣毳� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞚� Current Report鞐� 彀胳“搿� 韽暔霅橃毵�, Form 8-K 氤鸽鞐愲姅 旮办磮 鞛 靾橃箻雮� 響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
頃措嫻 鞝滌稖靹滊電� 觳秬氍胳劀毳� 韽暔頃� 鞝曤炒臧� Section 18 of the Exchange Act鞚� 氇╈爜靸� "鞝涤稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婌姷雼堧嫟"霛缄碃 氇呾嫓鞝侅溂搿� 氚濏瀳瓿� 鞛堨溂氅�, 韸轨爼頃� 鞏戈笁鞚� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婌潉 瓴冹澊霛缄碃 氇呾嫓頃╇媹雼�. 氤搓碃靹滊姅 霕愴暅 須岇偓毳� emerging growth company搿� 鞁濍硠頃橁碃 鞛堨溂氅�, 攴� 歃濌秾鞚� Nasdaq鞐愳劀 Common Stock (HUMA) 氚� Redeemable Warrants (HUMAW)搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Exhibit 99.1瓿� Cover Page Interactive Data File (Exhibit 104)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Humacyte, Inc. a diffus茅 un communiqu茅 de presse faisant 茅tat de ses r茅sultats financiers pour le deuxi猫me trimestre fiscal clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et est incorpor茅 par renvoi dans ce Current Report, mais le corps du formulaire 8-K n'inclut pas les chiffres financiers ou les tableaux sous-jacents.
Le document pr茅cise explicitement que les informations, y compris l'annexe, "ne doivent pas 锚tre consid茅r茅es comme 诲茅辫辞蝉茅别蝉" aux fins de la Section 18 de l'Exchange Act et ne seront pas incorpor茅es par renvoi dans d'autres d茅p么ts sauf par r茅f茅rence sp茅cifique. Le rapport identifie 茅galement la soci茅t茅 comme une emerging growth company et indique ses titres comme Common Stock (HUMA) et Redeemable Warrants (HUMAW) sur le Nasdaq. Le d茅p么t comprend l'Exhibit 99.1 et le Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. hat eine Pressemitteilung mit den Finanzergebnissen f眉r das am 30. Juni 2025 endende zweite Gesch盲ftsquartal ver枚ffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und wird in diesen Current Report durch Verweis aufgenommen, doch der Text des Formulars 8-K enth盲lt nicht die zugrundeliegenden Finanzkennzahlen oder Tabellen.
Die Einreichung stellt ausdr眉cklich fest, dass die Informationen, einschlie脽lich des Anhangs, "nicht als eingereicht gelten" im Sinne von Section 18 des Exchange Act und nicht durch Verweis in andere Einreichungen aufgenommen werden, au脽er durch ausdr眉ckliche Nennung. Der Bericht bezeichnet das Unternehmen au脽erdem als emerging growth company und f眉hrt seine Wertpapiere als Common Stock (HUMA) und Redeemable Warrants (HUMAW) an der Nasdaq auf. Der Einreichung sind Exhibit 99.1 und die Cover Page Interactive Data File (Exhibit 104) beigef眉gt.
FAQ
What did Humacyte (HUMA) disclose in this Form 8-K?
Is the press release included in the filing considered "filed" with the SEC?
Which exhibits were attached to the Humacyte 8-K?
Does this 8-K include financial statements or tables for Q2 2025?
What securities of Humacyte are listed and on which exchange?
